NASDAQ: SRDX
Surmodics Inc Stock Forecast, Predictions & Price Target

Analyst price target for SRDX

Based on 1 analyst offering 12 month price targets for Surmodics Inc

Min Forecast
$43.00+41.54%
Avg Forecast
$43.00+41.54%
Max Forecast
$43.00+41.54%

Should I buy or sell SRDX stock?

Based on 1 analyst offering ratings for Surmodics Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SRDX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SRDX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SRDX stock forecasts and price targets.

SRDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-07

1 of 1

Forecast return on equity

Is SRDX forecast to generate an efficient return?

Company
10.62%
Industry
23.25%
Market
63.15%
SRDX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SRDX forecast to generate an efficient return on assets?

Company
7.25%
Industry
12.4%
SRDX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRDX earnings per share forecast

What is SRDX's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$0.20
Avg 2 year Forecast
$0.76
Avg 3 year Forecast
$0.83

SRDX revenue forecast

What is SRDX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$135.4M+7.93%
Avg 2 year Forecast
$150.2M+19.75%
Avg 3 year Forecast
$169.9M+35.46%
SRDX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SRDX revenue growth forecast

How is SRDX forecast to perform vs Medical Devices companies and vs the US market?

Company
9.94%
Industry
8.12%
Market
11.02%
SRDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SRDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SRDX vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
SRDX$30.38$43.00+41.54%Strong Buy
DCTH$13.72$22.00+60.35%Strong Buy
NPCE$12.02$16.20+34.78%Strong Buy
PACB$1.30$2.80+115.38%Buy
SENS$0.74$2.00+169.91%Buy

Surmodics Stock Forecast FAQ

Is Surmodics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SRDX) stock is to Strong Buy SRDX stock.

Out of 1 analyst, 1 (100%) are recommending SRDX as a Strong Buy, 0 (0%) are recommending SRDX as a Buy, 0 (0%) are recommending SRDX as a Hold, 0 (0%) are recommending SRDX as a Sell, and 0 (0%) are recommending SRDX as a Strong Sell.

If you're new to stock investing, here's how to buy Surmodics stock.

What is SRDX's earnings growth forecast for 2025-2027?

(NASDAQ: SRDX) Surmodics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 25.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 24.08%.

Surmodics's earnings in 2025 is -$14,407,000.On average, 2 Wall Street analysts forecast SRDX's earnings for 2025 to be $2,859,200, with the lowest SRDX earnings forecast at $2,716,240, and the highest SRDX earnings forecast at $3,002,160. On average, 2 Wall Street analysts forecast SRDX's earnings for 2026 to be $10,864,958, with the lowest SRDX earnings forecast at $10,864,958, and the highest SRDX earnings forecast at $10,864,958.

In 2027, SRDX is forecast to generate $11,865,678 in earnings, with the lowest earnings forecast at $11,865,678 and the highest earnings forecast at $11,865,678.

What is SRDX's revenue growth forecast for 2025-2027?

(NASDAQ: SRDX) Surmodics's forecast annual revenue growth rate of 9.94% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.02%.

Surmodics's revenue in 2025 is $125,448,000.On average, 2 Wall Street analysts forecast SRDX's revenue for 2025 to be $1,935,606,649, with the lowest SRDX revenue forecast at $1,934,105,569, and the highest SRDX revenue forecast at $1,937,107,729. On average, 2 Wall Street analysts forecast SRDX's revenue for 2026 to be $2,147,544,820, with the lowest SRDX revenue forecast at $2,133,391,782, and the highest SRDX revenue forecast at $2,161,697,858.

In 2027, SRDX is forecast to generate $2,429,318,940 in revenue, with the lowest revenue forecast at $2,429,318,940 and the highest revenue forecast at $2,429,318,940.

What is SRDX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: SRDX) forecast ROA is 7.25%, which is lower than the forecast US Medical Devices industry average of 12.4%.

What is SRDX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SRDX price target, the average SRDX price target is $43.00, with the highest SRDX stock price forecast at $43.00 and the lowest SRDX stock price forecast at $43.00.

The Wall Street analyst predicted that Surmodics's share price could reach $43.00 by Mar 7, 2026. The average Surmodics stock price prediction forecasts a potential upside of 41.54% from the current SRDX share price of $30.38.

What is SRDX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SRDX) Surmodics's current Earnings Per Share (EPS) is -$1.02. On average, analysts forecast that SRDX's EPS will be $0.20 for 2025, with the lowest EPS forecast at $0.19, and the highest EPS forecast at $0.21. On average, analysts forecast that SRDX's EPS will be $0.76 for 2026, with the lowest EPS forecast at $0.76, and the highest EPS forecast at $0.76. In 2027, SRDX's EPS is forecast to hit $0.83 (min: $0.83, max: $0.83).

What is SRDX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: SRDX) forecast ROE is 10.62%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.